Current reviews in clinical and experimental pharmacology
2023
Rabeet Tariq
5 citations
Psychedelics might be the oldest psychoactive agents known to be used for inducing religious or mystical experiences. Their strong psychoactive effect was discovered accidentally in 1943 after the synthesis of Lysergic acid diethylamide (LSD) in 1937. These drugs became a mainstream area of research following the synthesis of LSD; however, several political and social factors led to their ban...
Open Journal of Medical Psychology
2023
John R. Rossiter
1 citation
Objective: Psychedelic drug therapy is banned in all countries of the world except Australia, where the government regulatory watchdog, the Therapeutic Goods Administration, is planning to allow approved psychiatrists, as of July 1, 2023, to prescribe psilocybin to treat depression and MDMA to treat post-traumatic stress disorder, a move precipitated by the U.S. Food and Drug Administration’s...
Bulletin of Taras Shevchenko National University of Kyiv Psychology
2023
Nadiia Omelchenko, Anton Kurapov
1 citation
Background. As a result of the military attack in Ukraine, both the military and civilian population are facing mental health disorders such as post-traumatic stress disorder (PTSD), depression, anxiety, and panic attacks. Classical psychotherapy and psychiatry are often ineffective in treating these conditions. In the United States and Europe, a significant amount of research is being...
The Meducator
2023
Alam Mehrjerdi Zahra, Bhavana Soma
2 citations
Psilocybin is a naturally occurring compound present in numerous mushroom species characterised by its hallucinogenic and psychedelic effects. Although it has a negative reputation, psilocybin has demonstrated therapeutic potential for treating mental health disorders by allowing the brain to make new neural connections which help the neural pathways adapt and break out of certain cognitive...
Frontiers in Pain Research
2023
Daniella Batievsky, Michelle Weiner, Shari B Kaplan et al.
8 citations
Chronic pain and depression diagnoses are skyrocketing. There is an urgent need for more effective treatments. Ketamine was recently established to alleviate pain and depression, but many gaps remain in the scientific literature. This paper reports the findings of an observational preliminary study that explored the efficacy of ketamine-assisted psychotherapy (KAPT) for chronic pain/major...
International Review of Psychiatry
2023
Fabio Carezzato, Ilana Falcão de Arruda, Caio Petrus Monteiro Figueiredo et al.
4 citations
This comprehensive review delves into the intricate interplay between gender/sex and MDMA use, drawing upon recent evidence. It explores how girls, as a means of coping with negative emotions, often resort to drug use, while boys primarily initiate drug use due to peer pressure or sensation-seeking tendencies. Women, frequently having endured traumatic life events, may turn to MDMA as a form of...
Frontiers in Psychology
2023
Julia C. Basso, Medha K. Satyal, Kevin L Mckee et al.
5 citations
Dissociation is a conscious state characterized by alterations in sensation and perception and is thought to arise from traumatic life experiences. Previous research has demonstrated that individuals with high levels of dissociation show impairments in cognitive-emotional processes. Therefore, using the Competing Neurobehavioral Decisions System (CNDS) theory, we used statistical modeling to...
American Journal of Geriatric Psychiatry
2023
C Bree Johnston, Maria Mangini, Charles S. Grob et al.
33 citations
Psychedelics and related compounds have shown efficacy for the treatment of a variety of conditions that are prevalent among older adults, including mood disorders, the psychological distress associated with a serious medical illness, post-traumatic stress disorder (PTSD), and prolonged grief disorder. Psychedelics also have properties that could help provide therapeutic benefits for patients...
Journal of Psychopharmacology
2023
Brent M Kious, Zach Schwartz, Benjamin R. Lewis
44 citations
Psychedelic research is proceeding rapidly, despite ongoing legal and regulatory barriers and lingering questions about study design, such as the difficulty of ensuring adequate blinding, the relative overrepresentation in studies of participants who have previously used psychedelics, and the importance of personal experience with psychedelics for those who provide psychedelic-assisted therapy....
Perspectives in biology and medicine
2023
Gail A. Edelsohn, Dominic Sisti
8 citations
Recent clinical trials of psychedelic drugs aim to treat a range of psychiatric conditions in adults. MDMA and psilocybin administered with psychotherapy have received FDA designation as "breakthrough therapies" for post-traumatic stress disorder (PTSD) and treatment-resistant depression (TRD) respectively. Given the potential benefit for minors burdened with many of the same disorders, calls...